CD5 and B-cell chronic lymphocytic leukemia: To dissect the regulatory basis of the ibrutinib-induced changes in the CLL cell transcriptomes and immunophenotypes, we performed ATAC-seq on FACS-purified CD19+CD5+ cells over the ibrutinib time course (Fig. 2a, Supplementary Fig. 7, and Supplementary Data 6).